Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
14,486.00    188.00 (1.31%)
Bid:
14,484.00
Ask:
14,486.00
Spread: 2.00 (0.014%)
Market Cap: £224.66b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Director/PDMR Shareholding

23 Nov 2023 15:00

RNS Number : 5087U
AstraZeneca PLC
23 November 2023

23 November 15:00 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that, on 22 November, it was notified of the following transactions in the Company's ordinary shares of $0.25 each (Ordinary Shares) by Michel Demaré, Non-Executive Chair of the Board.

PDMR

Position

Nature of the transaction

Date

Quantity

Price

Michel Demaré

Non-Executive Chair of the Board

Purchase of Ordinary Shares

21/11/2023

1,000

GB£101.05

Michel Demaré

Non-Executive Chair of the Board

Purchase of Ordinary Shares

22/11/2023

1,000

GB£101.70

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michel Demaré

2

Reason for the notification

a)

Position/status

Non-Executive Chair of the Board

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

AstraZeneca PLC

b)

LEI

PY6ZZQWO2IZFZC3IOL08

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of US$0.25 each in AstraZeneca PLC

GB0009895292

b)

Nature of the transaction

Purchase of AstraZeneca PLC Ordinary Shares of US$0.25

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£101.05224

1,000

d)

Aggregated information

- Aggregated volume

- Price

Not applicable - single transaction

e)

Date of the transaction

21 November 2023

f)

Place of the transaction

LON

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michel Demaré

2

Reason for the notification

a)

Position/status

Non-Executive Chair of the Board

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

AstraZeneca PLC

b)

LEI

PY6ZZQWO2IZFZC3IOL08

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of US$0.25 each in AstraZeneca PLC

GB0009895292

b)

Nature of the transaction

Purchase of AstraZeneca PLC Ordinary Shares of US$0.25

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£101.70

1,000

d)

Aggregated information

- Aggregated volume

- Price

Not applicable - single transaction

e)

Date of the transaction

22 November 2023

f)

Place of the transaction

LON

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian KempCompany Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHUORSROSUAUAA
Date   Source Headline
8th Jan 20267:00 amRNSAZN new Head of Investor Relations Joris Silon
2nd Jan 20263:00 pmRNSTotal Voting Rights
22nd Dec 202511:00 amRNSDirector/PDMR Shareholding
22nd Dec 202511:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:05 amRNSSubcutaneous Saphnelo approved in EU
16th Dec 20257:00 amRNSEnhertu approved in US for 1L HER2+ metastatic BC
4th Dec 20253:00 pmRNSHolding(s) in Company
1st Dec 20253:05 pmRNSBlock listing Interim Review
1st Dec 20253:00 pmRNSTotal Voting Rights
26th Nov 20257:00 amRNSImfinzi approved in US for early gastric cancer
24th Nov 20257:00 amRNSAstraZeneca manufacturing investment in Maryland
20th Nov 20257:00 amRNSKoselugo (selumetinib) approved in the US
17th Nov 20253:00 pmRNSHolding(s) in Company
14th Nov 202511:00 amRNSDirector/PDMR Shareholding
10th Nov 20253:00 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNS9M and Q3 2025 results
3rd Nov 20254:00 pmRNSResult of General Meeting
3rd Nov 20253:00 pmRNSTotal Voting Rights
28th Oct 20257:05 amRNSDirector Declaration
28th Oct 20257:00 amRNSKoselugo (selumetinib) approved in the EU
22nd Oct 20257:00 amRNSTezspire Approved in EU for CRSwNP
20th Oct 20257:05 amRNSUS FDA Approves Tezspire in CRSwNP
20th Oct 20257:00 amRNSPositive CHMP opinion for subcutaneous Saphnelo
13th Oct 20257:00 amRNSAgreement with US Govt to lower medicine prices
7th Oct 20257:00 amRNSBaxdrostat met primary endpoint in Bax24 Ph3 trial
6th Oct 20257:30 amRNSDatroway improved OS and PFS in TROPION-Breast02
1st Oct 20253:00 pmRNSTotal Voting Rights
29th Sep 20257:30 amRNSEnhertu improved IDFS in early BC in DB-05
29th Sep 20257:00 amRNSAZN harmonises listing structure
25th Sep 20254:30 pmRNSDirector/PDMR Shareholding
22nd Sep 20257:05 amRNSKoselugo recommended for EU approval
22nd Sep 20257:00 amRNSTezspire Recommended for Approval in EU for CRSwNP
17th Sep 20257:05 amRNSSaphnelo met primary endpoint in TULIP-SC
17th Sep 20257:00 amRNSUpdate on RESOLUTE Phase III trial
1st Sep 20253:00 pmRNSTotal Voting Rights
28th Aug 20253:00 pmRNSHolding(s) in Company
26th Aug 20253:00 pmRNSHolding(s) in Company
21st Aug 20253:00 pmRNSHolding(s) in Company
18th Aug 20253:00 pmRNSDirector/PDMR Shareholding
15th Aug 20253:00 pmRNSHolding(s) in Company
12th Aug 20253:00 pmRNSHolding(s) in Company
1st Aug 20253:00 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSH1 and Q2 2025 results
24th Jul 20257:00 amRNSGefurulimab nanobody met Phase III endpoints

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.